Peter H. O'Donnell, M.D., is an Assistant Professor of Medicine and principal investigator of The 1,200 Patients Project at The University of Chicago. He is also Associate Director for Clinical Implementation in The University of Chicago Center for Personalized Therapeutics.
Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”
Article first published online: 10 MAR 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Special Issue: Implementation of Genomic Medicine
Volume 166, Issue 1, pages 68–75, March 2014
How to Cite
2014. Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”. Am J Med Genet Part C Semin Med Genet 166C:68–75., , , , , , , , , , , , , , .
Conflict of interest disclosure: M.J.R. is a coinventor holding patents related to pharmacogenetic diagnostics and receives royalties related to UGT1A1 genotyping. No royalties are received from the genotyping performed in this study.
* Correspondence to: Peter H. O'Donnell, M.D., 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637. E-mail: email@example.com
- Issue published online: 18 MAR 2014
- Article first published online: 10 MAR 2014
- NIH. Grant Numbers: K23, GM100288-01A1, K12, CA139160
- Bucksbaum Institute Associate Faculty Scholar Pilot
- The Conquer Cancer Foundation of the American Society for Clinical Oncology
- The William F. O'Connor Foundation
- genomic medicine;
- precision medicine
Pharmacogenomic testing is viewed as an integral part of precision medicine. To achieve this, we originated The 1,200 Patients Project which offers broad, preemptive pharmacogenomic testing to patients at our institution. We analyzed enrollment, genotype, and encounter-level data from the first year of implementation to assess utility of providing pharmacogenomic results. Results were delivered via a genomic prescribing system (GPS) in the form of traffic lights: green (favorable), yellow (caution), and red (high risk). Additional supporting information was provided as a virtual pharmacogenomic consult, including citation to relevant publications. Currently, 812 patients have participated, representing 90% of those approached; 608 have been successfully genotyped across a custom array. A total of 268 clinic encounters have occurred at which results were accessible via the GPS. At 86% of visits, physicians accessed the GPS, receiving 367 result signals for medications patients were taking: 57% green lights, 41% yellow lights, and 1.4% red lights. Physician click frequencies to obtain clinical details about alerts varied according to color severity (100% of red were clicked, 72% yellow, 20% green). For 85% of visits, clinical pharmacogenomic information was available for at least one drug the patient was taking, suggesting relevance of the delivered information. We successfully implemented an individualized health care model of preemptive pharmacogenomic testing, delivering results along with pharmacogenomic decision support. Patient interest was robust, physician adoption of information was high, and results were routinely utilized. Ongoing examination of a larger number of clinic encounters and inclusion of more physicians and patients is warranted. © 2014 Wiley Periodicals, Inc.